Department of Pediatric Cardiology, Koç University School of Medicine, Istanbul, Turkey.
Department of Pediatrics, Koç University, Istanbul, Turkey.
Cardiol Young. 2022 Oct;32(10):1609-1615. doi: 10.1017/S1047951121004650. Epub 2021 Dec 10.
The rate of morbidity and mortality related to pulmonary regurgitation and pulmonary stenosis are big concerns after the surgery for CHD. Percutaneous pulmonary valve implantation has been established as a less invasive technique compared to surgery with promising results according to long-term follow-up of the patients. There are only two approved valve options for percutaneous pulmonary valve implantation until now, which are Melody (Medtronic, Minneapolis, Minn, USA) and Sapien (Edwards Lifesciences, Irvine, Ca, USA). Both valves have limitations and do not cover entire patient population. Therefore, the cardiologists need more options to improve outcomes with fewer complications in a such promising area. Herein, we present a case series applying for pulmonary position in conduits and native right ventricular outflow tract of a new transcatheter valve system Myval ® which is designed for transcatheter aortic valve implantation procedures. This is the first patient series in which the use of Myvalv in dysfunctional right ventricular outflow tracts is described, after surgical repair of CHD.
肺动脉瓣反流和肺动脉瓣狭窄相关的发病率和死亡率是先心病手术后的主要关注点。与手术相比，经皮肺动脉瓣植入术是一种创伤较小的技术，根据患者的长期随访结果显示具有良好的效果。直到目前为止，只有两种经皮肺动脉瓣植入术的批准瓣膜选择，即 Melody（美敦力，明尼苏达州明尼阿波利斯）和 Sapien（爱德华兹生命科学公司，加利福尼亚州欧文）。这两种瓣膜都有局限性，不能覆盖整个患者群体。因此，心脏病专家需要更多的选择，以便在这一前景广阔的领域中以更少的并发症改善治疗效果。在此，我们报告了一系列应用于导管和原生右心室流出道的新型经导管瓣膜系统 Myval ® 的病例，该系统专为经导管主动脉瓣植入术设计。这是先心病手术后，首次描述使用 Myvalv 治疗右心室流出道功能障碍的病例系列。
